Curis Inc. filings document the regulatory record of a biotechnology company focused on emavusertib (CA-4948) and related oncology-development activities. Form 8-K disclosures cover financial results, clinical and regulatory updates, material agreements, capital-structure matters and Nasdaq listing-compliance notices.
Proxy and other filings describe shareholder voting matters, authorized-share proposals, securities issuances tied to preferred stock and warrant instruments, equity incentive plans, executive compensation and governance procedures. The filing record also includes pro forma financial information related to the completed sale of the company’s interest in Curis Royalty, LLC.
Curis, Inc. reported a sharply improved 2025 bottom line, with full-year net loss narrowing to $7.6 million ($0.58 per share) from $43.4 million in 2024, and fourth-quarter 2025 net income of $19.4 million versus a prior-year loss of $9.6 million. Results were driven largely by a non-cash $27.2 million gain from extinguishing the liability tied to the sale of future Erivedge royalties, after Curis sold its Erivedge-related interests and is no longer entitled to royalty revenues. Research and development and general and administrative expenses both declined year over year. As of December 31, 2025, cash and cash equivalents were $5.1 million with about 12.9 million shares outstanding. A January 2026 PIPE financing provides up to $80.8 million in potential gross proceeds, and Curis estimates its cash, including $20.2 million already received and up to $20.2 million from potential Series B warrant exercises, should fund operations into the second half of 2027. The company also notes it does not have sufficient cash on hand to support current operations for 12 months from the press release date and will require substantial additional capital to advance emavusertib.
CURIS INC Chief Development Officer Jonathan B. Zung reported acquiring new equity-linked awards. He received 50 shares of Series B Convertible Preferred Stock, which automatically convert into 66,667 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to Beneficial Ownership Limitations and other terms.
In connection with this, he also acquired Series A, Series B and Series C Warrants, each covering 66,667 shares of Common Stock at an exercise price of $0.75 per share. The warrants became immediately exercisable following receipt of requisite stockholder approval and a certificate of amendment filing on March 17, 2026, with the Series B Warrants featuring an exercise period tied to dosing milestones in a Phase 2 clinical trial of emavusertib.
Curis Inc’s CMO, Ahmed Hamdy, reported new equity-linked awards. He acquired 50 shares of Series B Convertible Preferred Stock, which automatically convert into 66,667 shares of common stock at 5 p.m. Eastern Time on March 20, 2026, subject to stated beneficial ownership limits.
He also received 66,667 Series A Warrants, 66,667 Series B Warrants and 66,667 Series C Warrants, each initially exercisable for common stock at an exercise price of $0.75 per share. The securities were sold at $1,000 per Security to him and became exercisable following requisite stockholder approval and a certificate of amendment filing. The Series B Warrants have a termination date tied to dosing the fifth patient in a Phase 2 emavusertib trial and may have their exercise price reset, within limits, if the stock trades below $0.75 at that time.
CURIS INC CFO Diantha Duvall received a grant of Series B Convertible Preferred Stock and multiple warrant series linked to Common Stock. On March 17, 2026, she acquired 50 shares of Series B Convertible Preferred Stock, which are set to automatically convert into 66,666 shares of Common Stock at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations and applicable Beneficial Ownership Limitations.
She was also granted 66,666 Series A Warrants, 66,666 Series B Warrants and 66,666 Series C Warrants, each exercisable for Common Stock with an exercise price of $0.75 per share. The Series A and Series C Warrants became immediately exercisable following receipt of Requisite Stockholder Approval and a Certificate of Amendment filing on March 17, 2026. The Series B Warrants became immediately exercisable on the same approval and will terminate 30 days after the company announces dosing of the fifth patient in a Phase 2 clinical trial, with provisions that may reset the exercise price and extend the termination date based on the Common Stock closing sale price at that time.
Curis Inc. President & CEO James E. Dentzer reported awards of preferred stock and warrants linked to Curis common shares. He received 100 shares of Series B Convertible Non-Redeemable Preferred Stock, with each preferred share automatically converting into 1,333.33 common shares for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to Beneficial Ownership Limitations.
He was also granted a Series A Warrant, a Series B Warrant and a Series C Warrant, each covering 133,333 shares of common stock at an exercise price of $0.75 per share and issued at no cost. The Series A and Series C Warrants became immediately exercisable after Requisite Stockholder Approval and a Certificate of Amendment filing on March 17, 2026. The Series B Warrants became immediately exercisable after the same approvals and will terminate 30 days after the company announces dosing of the fifth patient in its Phase 2 emavusertib trial, with a possible reset of the exercise price and a 30-day extension if the stock price is below $0.75 on that Initial Termination Date.
CURIS INC director Marc Rubin reported grants of new preferred stock and warrants linked to common shares. On March 17, 2026, he received 20 shares of Series B Convertible Preferred Stock, which automatically convert into 26,667 shares of common stock for no additional payment at 5 p.m. Eastern Time on March 20, 2026, subject to stated beneficial ownership limits.
He was also granted Series A, Series B and Series C warrants, each for 26,667 common shares at an exercise price of $0.75 per share. The Series A and Series C warrants became immediately exercisable upon receipt of required stockholder approval and a certificate of amendment filing, while the Series B warrants are exercisable on similar conditions but have a termination date tied to dosing milestones in a Phase 2 clinical trial and may have their exercise price reset and term extended based on the stock price at that milestone.
Curis, Inc. stockholders approved a major increase in the company’s authorized capital and a new long-term equity incentive plan at a special meeting held as a virtual conference.
The amendment to the Restated Certificate of Incorporation raises authorized capital stock from 73,343,750 to 288,757,150 shares and authorized common stock from 68,343,750 to 283,757,150 shares. Stockholders also approved the 2026 Incentive Plan, initially covering 6,407,374 shares plus up to 3,474,867 additional shares from expiring or forfeited prior awards, an annual “evergreen” increase of up to 5% of specified equity outstanding from 2027 through 2036, and up to 25,000,000 shares for incentive stock options. In accordance with Nasdaq Listing Rules 5635(c) and (d), they approved issuing common shares upon conversion of Series B Preferred Stock and exercises of Series A, B and C Warrants (or in some cases pre-funded warrants).
Curis, Inc. is calling a virtual special stockholder meeting on March 17, 2026 to vote on several major capital and compensation proposals. Stockholders will decide whether to amend the certificate of incorporation to increase authorized capital stock from 73,343,750 to 288,757,150 shares, including an increase in authorized common stock from 68,343,750 to 283,757,150 shares. They will also vote on approving, under Nasdaq rules, the issuance of up to 26,926,675 shares of common stock upon conversion of 20,195 shares of Series B preferred stock and up to 80,780,025 shares upon exercise of Series A, B and C warrants issued in a January 2026 PIPE financing, all at a $0.75 exercise price. The PIPE has already delivered about $20.2 million in gross proceeds and could add approximately $60.6 million if all warrants are exercised. A new 2026 Incentive Plan is proposed with an initial 6,407,374-share pool plus a rollover from the prior plan and an evergreen feature of up to 5% of fully diluted equity per year through 2036. The board also seeks authority to adjourn the meeting if needed to obtain sufficient votes and recommends voting FOR all proposals.
Curis Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 1,336,876 shares, representing 9.99% of Curis common stock as of 12/31/2025.
The filing states Armistice Capital exercises shared voting and dispositive power over those 1,336,876 shares; the Master Fund is the direct holder and may receive dividends or sale proceeds.
Curis, Inc. is registering 107,706,700 shares of common stock for resale by investors who participated in a January 2026 private financing. These shares come from Series B preferred stock and Series A, B and C warrants (or related pre-funded warrants) that can convert into common stock.
The company will not receive proceeds from investors’ resale of these shares, though it will receive cash if warrants are exercised. Curis is a biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor being studied in lymphoma and chronic lymphocytic leukemia. Its stock trades on Nasdaq under the symbol CRIS.